. 2021 Oct 14;3(10):e0554. doi: 10.1097/CCE.0000000000000554

TABLE 3.

Combining Inflammatix-Severity-2 Metric With Clinical and Biochemical Indices to Predict 30-d Mortality and Adverse Clinical Outcomes

Multivariate Model	OR (95% CI)	p
30-d mortality^a
IMX-SEV-2 Severity metric (increase of 0.1)	1.92 (1.40–2.64)	< 0.0001
Charlson comorbidity index	1.36 (1.17–1.57)	< 0.0001
Adverse clinical outcome^b
IMX-SEV-2 Severity metric (increase of 0.1)	4.42 (2.14–9.17)	< 0.0001
Acute Physiology and Chronic Health Evaluation II	1.11 (1.05–1.18)	0.0003

IMX-SEV-2 = Inflammatix-Severity-2, OR= odds ratio.

^aArea under the receiver operating curve (AUROC) (95% CI) = 0.79 (0.71–0.87).

^bAUROC (95% CI) = 0.80 (0.74–0.87).

30-d Mortality: All biochemical and physiologic variables from patients meeting Sepsis-3 criteria were included in the multivariate logistic regression analysis. Only the InSep severity metric combined with the Charlson comorbidity index had independent predictive ability.

Adverse Clinical Outcome: The integrated outcomes included secondary infection, chronic critical illness, “poor” discharge disposition, and/or 30-d mortality. All biochemical and physiologic variables were included in the multivariate logistic regression analysis. The InSep severity metric combined with Acute Physiology and Chronic Health Evaluation II had independent predictive ability.